DelveInsight’s Complement 3 Glomerulopathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging complement 3 glomerulopathy drugs, market share of ...
Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...
Medpage Today on MSN
Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis
The trial tested two doses of claseprubart -- 300 mg and 600 mg -- and its primary endpoint was safety. Secondary outcomes included scores on the Myasthenia-Gravis Activities of Daily Living (MG-ADL) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback